Cancer Clinical Trial -Storm Therapeutics-STC15-22101

A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmokinetics,  and Clinical Activity Of STC-15, a METTL-3 Inhibitor, in Subjects with Advanced MAlignanciesEfficac

Drug

STC-15

Phase

Phase I

Condition

Advanced Malignancies

Keywords

RNA m6A modification/METTL3 inhibition